Search

Your search keyword '"Stilgenbauer, Stephan"' showing total 2,887 results
Start Over Author "Stilgenbauer, Stephan"
2,887 results on '"Stilgenbauer, Stephan"'

52. Venetoclax Initiation in Chronic Lymphocytic Leukemia: International Insights and Innovative Approaches for Optimal Patient Care

Author

Anderson, Mary Ann, primary, Walewska, Renata, additional, Hackett, Fidelma, additional, Kater, Arnon P., additional, Montegaard, Josie, additional, O’Brien, Susan, additional, Seymour, John F., additional, Smith, Matthew, additional, Stilgenbauer, Stephan, additional, Whitechurch, Ashley, additional, and Brown, Jennifer R., additional

Published
2024
Full Text
View/download PDF

53. SOP bowel dysfunction in palliative care medicine

Author

Ettrich, Thomas, primary, Schönsteiner, Stefan, additional, Mayer-Steinacker, Regine, additional, Stilgenbauer, Stephan, additional, Gog, Christiane, additional, Thuss-Patience, Peter, additional, Wolf, Carolin, additional, and Ostgathe, Christoph, additional

Published
2024
Full Text
View/download PDF

54. An Updated Comparison of Overall Survival with Brexucabtagene Autoleucel (Brexu-cel) CAR T-Cell Therapy (ZUMA-2) Versus Standard of Care (SCHOLAR-2) in Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor (BTKi)

Author

Hess, Georg, primary, Dreyling, Martin, additional, Oberic, Lucie, additional, Gine, Eva, additional, Zinzani, Pier Luigi, additional, Linton, Kim M, additional, Vilmar, Adam, additional, Jerkeman, Mats, additional, Chen, Jenny M H, additional, Ohler, Anke, additional, Stilgenbauer, Stephan, additional, Thieblemont, Catherine, additional, Lambert, Jonathan, additional, Zilioli, Vittorio Ruggero, additional, Sancho, Juan-Manuel, additional, Jimenez-Ubieto, Ana, additional, Fischer, Luca, additional, Eyre, Toby A, additional, Keeping, Sam, additional, Park, Julie E, additional, Wu, James J, additional, Nunes, Ana, additional, Reitan, John, additional, Wade, Sally W, additional, and Salles, Gilles, additional

Published
2024
Full Text
View/download PDF

55. Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial

Author

Zoellner, Anna-Katharina, Unterhalt, Michael, Stilgenbauer, Stephan, Hübel, Kai, Thieblemont, Catherine, Metzner, Bernd, Topp, Max, Truemper, Lorenz, Schmidt, Christian, Bouabdallah, Kamal, Krauter, Jürgen, Lenz, Georg, Dürig, Jan, Vergote, Vibeke, Schäfer-Eckart, Kerstin, André, Marc, Kluin-Nelemans, Hanneke C, van Hoof, Achiel, Klapper, Wolfram, Hiddemann, Wolfgang, Dreyling, Martin, and Hoster, Eva

Published
2021
Full Text
View/download PDF

56. IGLV3-21*01 is an inherited risk factor for CLL through the acquisition of a single-point mutation enabling autonomous BCR signaling

Author

Maity, Palash C., Bilal, Mayas, Koning, Marvyn T., Young, Marc, van Bergen, Cornelis A. M., Renna, Valerio, Nicolò, Antonella, Datta, Moumita, Gentner-Göbel, Eva, Barendse, Rob S., Somers, Sebastiaan F., de Groen, Ruben A. L., Vermaat, Joost S. P., Steinbrecher, Daniela, Schneider, Christof, Tausch, Eugen, Bittolo, Tamara, Bomben, Riccardo, Mazzarello, Andrea Nicola, del Poeta, Giovanni, Kroes, Wilma G. M., van Wezel, J. Tom, Imkeller, Katharina, Busse, Christian E., Degano, Massimo, Bakchoul, Tamam, Schulz, Axel Ronald, Mei, Henrik, Ghia, Paolo, Kotta, Konstantia, Stamatopoulos, Kostas, Wardemann, Hedda, Zucchetto, Antonella, Chiorazzi, Nicholas, Gattei, Valter, Stilgenbauer, Stephan, Veelken, Hendrik, and Jumaa, Hassan

Published
2020

57. EOMES and IL-10 regulate antitumor activity of T regulatory type 1 CD4+ T cells in chronic lymphocytic leukemia

Author

Roessner, Philipp M., Llaó Cid, Laura, Lupar, Ekaterina, Roider, Tobias, Bordas, Marie, Schifflers, Christoph, Arseni, Lavinia, Gaupel, Ann-Christin, Kilpert, Fabian, Krötschel, Marit, Arnold, Sebastian J., Sellner, Leopold, Colomer, Dolors, Stilgenbauer, Stephan, Dietrich, Sascha, Lichter, Peter, Izcue, Ana, and Seiffert, Martina

Published
2021
Full Text
View/download PDF

58. Mutational mechanisms shaping the coding and noncoding genome of germinal center derived B-cell lymphomas

Author

Hübschmann, Daniel, Kleinheinz, Kortine, Wagener, Rabea, Bernhart, Stephan H., López, Cristina, Toprak, Umut H., Sungalee, Stephanie, Ishaque, Naveed, Kretzmer, Helene, Kreuz, Markus, Waszak, Sebastian M., Paramasivam, Nagarajan, Ammerpohl, Ole, Aukema, Sietse M., Beekman, Renée, Bergmann, Anke K., Bieg, Matthias, Binder, Hans, Borkhardt, Arndt, Borst, Christoph, Brors, Benedikt, Bruns, Philipp, Carrillo de Santa Pau, Enrique, Claviez, Alexander, Doose, Gero, Haake, Andrea, Karsch, Dennis, Haas, Siegfried, Hansmann, Martin-Leo, Hoell, Jessica I., Hovestadt, Volker, Huang, Bingding, Hummel, Michael, Jäger-Schmidt, Christina, Kerssemakers, Jules N. A., Korbel, Jan O., Kube, Dieter, Lawerenz, Chris, Lenze, Dido, Martens, Joost H. A., Ott, German, Radlwimmer, Bernhard, Reisinger, Eva, Richter, Julia, Rico, Daniel, Rosenstiel, Philip, Rosenwald, Andreas, Schillhabel, Markus, Stilgenbauer, Stephan, Stadler, Peter F., Martín-Subero, José I., Szczepanowski, Monika, Warsow, Gregor, Weniger, Marc A., Zapatka, Marc, Valencia, Alfonso, Stunnenberg, Hendrik G., Lichter, Peter, Möller, Peter, Loeffler, Markus, Eils, Roland, Klapper, Wolfram, Hoffmann, Steve, Trümper, Lorenz, Küppers, Ralf, Schlesner, Matthias, and Siebert, Reiner

Published
2021
Full Text
View/download PDF

59. Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL

Author

Agathangelidis, Andreas, Chatzidimitriou, Anastasia, Gemenetzi, Katerina, Giudicelli, Veronique, Karypidou, Maria, Plevova, Karla, Davis, Zadie, Yan, Xiao-Jie, Jeromin, Sabine, Schneider, Christof, Pedersen, Lone Bredo, Tschumper, Renee C., Sutton, Lesley-Ann, Baliakas, Panagiotis, Scarfò, Lydia, van Gastel, Ellen J., Armand, Marine, Tausch, Eugen, Biderman, Bella, Baer, Constance, Bagnara, Davide, Navarro, Alba, Langlois de Septenville, Anne, Guido, Valentina, Mitterbauer-Hohendanner, Gerlinde, Dimovski, Aleksandar, Brieghel, Christian, Lawless, Sarah, Meggendorfer, Manja, Brazdilova, Kamila, Ritgen, Matthias, Facco, Monica, Tresoldi, Cristina, Visentin, Andrea, Patriarca, Andrea, Catherwood, Mark, Bonello, Lisa, Sudarikov, Andrey, Vanura, Katrina, Roumelioti, Maria, Skuhrova Francova, Hana, Moysiadis, Theodoros, Veronese, Silvio, Giannopoulos, Krzysztof, Mansouri, Larry, Karan-Djurasevic, Teodora, Sandaltzopoulos, Raphael, Bödör, Csaba, Fais, Franco, Kater, Arnon, Panovska, Irina, Rossi, Davide, Alshemmari, Salem, Panagiotidis, Panagiotis, Costeas, Paul, Espinet, Blanca, Antic, Darko, Foroni, Letizia, Montillo, Marco, Trentin, Livio, Stavroyianni, Niki, Gaidano, Gianluca, Francia di Celle, Paola, Niemann, Carsten, Campo, Elias, Anagnostopoulos, Achilles, Pott, Christiane, Fischer, Kirsten, Hallek, Michael, Oscier, David, Stilgenbauer, Stephan, Haferlach, Claudia, Jelinek, Diane, Chiorazzi, Nicholas, Pospisilova, Sarka, Lefranc, Marie-Paule, Kossida, Sofia, Langerak, Anton W., Belessi, Chrysoula, Davi, Frederic, Rosenquist, Richard, Ghia, Paolo, and Stamatopoulos, Kostas

Published
2021
Full Text
View/download PDF

61. Associations of ofatumumab exposure and treatment outcomes in patients with untreated CLL receiving chemoimmunotherapy

Author

Jewell, Roxanne C, Kipps, Thomas J, Dürig, Jan, Griskevicius, Laimonas, Stilgenbauer, Stephan, Smolej, Lukáš, Mayer, Jiří, Hess, Georg, Hernandez-Ilizaliturri, Francisco J, Padmanabhan-Iyer, Swaminathan, Fang, Lei, Goldstein, Nancy, Gorczyca, Michele, Gupta, Ira, Lisby, Steen, Wierda, William G, and Investigators, for the Hx-CD20-407 Study

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Hematology, Clinical Trials and Supportive Activities, Rare Diseases, Clinical Research, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adult, Aged, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological, Antineoplastic Combined Chemotherapy Protocols, Chromosome Aberrations, Drug Administration Schedule, Female, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Male, Middle Aged, Neoplasm Metastasis, Neoplasm Staging, Remission Induction, Treatment Outcome, Chemoimmunotherapy, chronic lymphocytic leukemia, ofatumumab, pharmacokinetics, Hx-CD20-407 Study Investigators, Clinical Sciences, Immunology, Cardiovascular medicine and haematology
Abstract

Relationships between patient characteristics, ofatumumab pharmacokinetics, and treatment outcomes were investigated in this phase 2 trial of ofatumumab plus fludarabine and cyclophosphamide (FC) in untreated chronic lymphocytic leukemia. Patients were randomized 1:1 to receive 500 or 1000 mg ofatumumab (Cycle 1; 300 mg) plus FC every 4 weeks for six cycles. Median Cmax and Ctrough values were similar at Cycle 1 regardless of the ultimate clinical outcome. At later doses, these values were higher for patients with complete response (CR) than for other patients. Higher Cmax and Ctrough values at Cycles 3 and 6 were significantly associated with an increased likelihood of CR, whereas ofatumumab pharmacokinetics were not associated with an objective response (OR) on the basis of univariate analyses. Multivariate analyses indicated that baseline patient/disease factors were predominantly associated with CR (17p status) or OR (bulky lymphadenopathy, gender, and serum thymidine kinase), rather than ofatumumab pharmacokinetics.Trial registrationwww.clinicaltrials.gov (NCT00410163).

Published
2017

62. Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation

Author

Kharfan-Dabaja, Mohamed A, Kumar, Ambuj, Hamadani, Mehdi, Stilgenbauer, Stephan, Ghia, Paolo, Anasetti, Claudio, Dreger, Peter, Montserrat, Emili, Perales, Miguel-Angel, Alyea, Edwin P, Awan, Farrukh T, Ayala, Ernesto, Barrientos, Jacqueline C, Brown, Jennifer R, Castro, Januario E, Furman, Richard R, Gribben, John, Hill, Brian T, Mohty, Mohamad, Moreno, Carol, O'Brien, Susan, Pavletic, Steven Z, Pinilla-Ibarz, Javier, Reddy, Nishitha M, Sorror, Mohamed, Bredeson, Christopher, Carpenter, Paul, and Savani, Bipin N

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Cancer, Transplantation, Hematology, Rare Diseases, Clinical Research, Clinical Trials and Supportive Activities, Lymphoma, Antineoplastic Agents, Child, Child, Preschool, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Practice Guidelines as Topic, Salvage Therapy, Transplantation Conditioning, Transplantation, Homologous, Chronic lymphocytic leukemia, Allogeneic hematopoietic cell transplantation, BCR inhibitors, BCL-2 inhibitors, Clinical Sciences, Immunology, Cardiovascular medicine and haematology
Abstract

We sought to establish clinical practice recommendations to redefine the role of allogeneic hematopoietic cell transplantation (allo-HCT) for patients with chronic lymphocytic leukemia (CLL) in an era of highly active targeted therapies. We performed a systematic review to identify prospective randomized controlled trials comparing allo-HCT against novel therapies for treatment of CLL at various disease stages. In the absence of such data, we invited physicians with expertise in allo-HCT and/or CLL to participate in developing these recommendations. We followed the Grading of Recommendations Assessment, Development and Evaluation methodology. For standard-risk CLL we recommend allo-HCT in the absence of response or if there is evidence of disease progression after B cell receptor (BCR) inhibitors. For high-risk CLL an allo-HCT is recommended after failing 2 lines of therapy and showing an objective response to BCR inhibitors or to a clinical trial. It is also recommended for patients who fail to show an objective response or progress after BCR inhibitors and receive BCL-2 inhibitors, regardless of whether an objective response is achieved. For Richter transformation, we recommend allo-HCT upon demonstration of an objective response to anthracycline-based chemotherapy. A reduced-intensity conditioning regimen is recommended whenever indicated. These recommendations highlight the rapidly changing treatment landscape of CLL. Newer therapies have disrupted prior paradigms, and allo-HCT is now relegated to later stages of relapsed or refractory CLL.

Published
2016

63. Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: Results of a prospective observational study

Author

Schetelig, Johannes, Hoek, Jennifer, Stilgenbauer, Stephan, Middeke, Jan Moritz, Andersen, Niels Smedegaard, Fox, Christopher P., Lenhoff, Stig, Volin, Liisa, Shimoni, Avichai, Schroyens, Wilfried, van Gelder, Michel, Bunjes, Donald, van Biezen, Anja, Baldauf, Henning, de Wreede, Liesbeth C., Tournilhac, Olivier, Kröger, Nicolaus, Yakoub-Agha, Ibrahim, and Dreger, Peter

Published
2021
Full Text
View/download PDF

65. Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2‐BCG): Final analysis of a multicenter, open‐label phase‐II‐trial.

Author

Cramer, Paula, von Tresckow, Julia, Fink, Anna‐Maria, Robrecht, Sandra, Giza, Adam, Tausch, Eugen, Müller, Lothar, Knauf, Wolfgang, Zingerle, Matthias, Al‐Sawaf, Othman, Langerbeins, Petra, Fischer, Kirsten, Kreuzer, Karl‐Anton, Kneba, Michael, Wendtner, Clemens‐Martin, Stilgenbauer, Stephan, Eichhorst, Barbara, and Hallek, Michael

Published
2024
Full Text
View/download PDF

68. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial

Author

Al-Sawaf, Othman, Zhang, Can, Tandon, Maneesh, Sinha, Arijit, Fink, Anna-Maria, Robrecht, Sandra, Samoylova, Olga, Liberati, Anna M, Pinilla-Ibarz, Javier, Opat, Stephen, Sivcheva, Liliya, Le Dû, Katell, Fogliatto, Laura M, Niemann, Carsten U, Weinkove, Robert, Robinson, Sue, Kipps, Thomas J, Tausch, Eugen, Schary, William, Ritgen, Matthias, Wendtner, Clemens-Martin, Kreuzer, Karl-Anton, Eichhorst, Barbara, Stilgenbauer, Stephan, Hallek, Michael, and Fischer, Kirsten

Published
2020
Full Text
View/download PDF

69. Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial*

Author

Wendtner, Clemens M, Hallek, Michael, Fraser, Graeme AM, Michallet, Anne-Sophie, Hillmen, Peter, Dürig, Jan, Kalaycio, Matt, Gribben, John G, Stilgenbauer, Stephan, Buhler, Andreas, Kipps, Thomas J, Purse, Brendan, Zhang, Jennie, De Bedout, Sabine, Mei, Jay, and Chanan-Khan, Asher

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Clinical Research, Clinical Trials and Supportive Activities, Patient Safety, Hematology, Lymphoma, Rare Diseases, Cancer, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Drug Resistance, Neoplasm, Female, Humans, Immunologic Factors, Kaplan-Meier Estimate, Lenalidomide, Leukemia, Lymphocytic, Chronic, B-Cell, Male, Middle Aged, Neoplasm Staging, Recurrence, Retreatment, Thalidomide, Treatment Outcome, Clinical trial, CLL, lenalidomide, phase II, Clinical Sciences, Immunology, Cardiovascular medicine and haematology
Abstract

The objective of this study was to evaluate the safety and efficacy of different lenalidomide starting doses in patients with relapsed/refractory chronic lymphocytic leukemia (CLL). CLL patients were randomized to receive lenalidomide at initial doses of 5, 10, or 15 mg/d (N = 103). Doses were escalated by 5 mg every 28-d up to a maximum of 25 mg/d; dose reductions in up to 5 mg decrements were permitted. The most common grade ≥3 adverse events (AEs) were neutropenia and thrombocytopenia. Ten patients died during therapy (four deaths considered as related to lenalidomide); 12 patients experienced second primary malignancies. The most common cause for treatment discontinuation was AEs. Overall response rates were similar across arms. Progression-free survival and overall survival rates were longer in patients who escalated treatment (to 15 or 20 mg/d) versus those who did not. Lower starting doses allowed subsequent dose escalation of lenalidomide while maintaining an acceptable tolerability profile in patients with relapsed/refractory CLL.

Published
2016

70. DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia

Author

Oakes, Christopher C, Seifert, Marc, Assenov, Yassen, Gu, Lei, Przekopowitz, Martina, Ruppert, Amy S, Wang, Qi, Imbusch, Charles D, Serva, Andrius, Koser, Sandra D, Brocks, David, Lipka, Daniel B, Bogatyrova, Olga, Weichenhan, Dieter, Brors, Benedikt, Rassenti, Laura, Kipps, Thomas J, Mertens, Daniel, Zapatka, Marc, Lichter, Peter, Döhner, Hartmut, Küppers, Ralf, Zenz, Thorsten, Stilgenbauer, Stephan, Byrd, John C, and Plass, Christoph

Subjects
Hematology, Genetics, Human Genome, Rare Diseases, Cancer, Lymphoma, Adult, Aged, Aged, 80 and over, B-Lymphocytes, Binding Sites, CpG Islands, DNA Methylation, Epigenesis, Genetic, Female, Gene Expression Regulation, Leukemic, Gene Expression Regulation, Neoplastic, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Male, Middle Aged, Neoplasm Proteins, Phenotype, Promoter Regions, Genetic, Biological Sciences, Medical and Health Sciences, Developmental Biology
Abstract

Charting differences between tumors and normal tissue is a mainstay of cancer research. However, clonal tumor expansion from complex normal tissue architectures potentially obscures cancer-specific events, including divergent epigenetic patterns. Using whole-genome bisulfite sequencing of normal B cell subsets, we observed broad epigenetic programming of selective transcription factor binding sites coincident with the degree of B cell maturation. By comparing normal B cells to malignant B cells from 268 patients with chronic lymphocytic leukemia (CLL), we showed that tumors derive largely from a continuum of maturation states reflected in normal developmental stages. Epigenetic maturation in CLL was associated with an indolent gene expression pattern and increasingly favorable clinical outcomes. We further uncovered that most previously reported tumor-specific methylation events are normally present in non-malignant B cells. Instead, we identified a potential pathogenic role for transcription factor dysregulation in CLL, where excess programming by EGR and NFAT with reduced EBF and AP-1 programming imbalances the normal B cell epigenetic program.

Published
2016

71. Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial

Author

Al-Sawaf, Othman, primary, Ligtvoet, Rudy, additional, Robrecht, Sandra, additional, Stumpf, Janina, additional, Fink, Anna-Maria, additional, Tausch, Eugen, additional, Schneider, Christof, additional, Boettcher, Sebastian, additional, Mikusko, Martin, additional, Ritgen, Matthias, additional, Schetelig, Johannes, additional, von Tresckow, Julia, additional, Vehling-Kaiser, Ursula, additional, Gaska, Tobias, additional, Wendtner, Clemens Martin, additional, Chapuy, Bjoern, additional, Fischer, Kirsten, additional, Kreuzer, Karl-Anton, additional, Stilgenbauer, Stephan, additional, Staber, Philipp, additional, Niemann, Carsten, additional, Hallek, Michael, additional, and Eichhorst, Barbara, additional

Published
2023
Full Text
View/download PDF

72. Relationship Between Venetoclax Exposure and Undetectable Minimal Residual Disease Rates in Relapsed/Refractory Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of Six Clinical Studies

Author

Gopalakrishnan, Sathej, primary, Menon, Rajeev, additional, Suleiman, Ahmed A., additional, Kater, Arnon P., additional, Stilgenbauer, Stephan, additional, Seymour, John F., additional, Chyla, Brenda, additional, Lu, Tong, additional, Young Kim, Su, additional, Roberts, Andrew W., additional, Woyach, Jennifer A., additional, Mensing, Sven, additional, and Salem, Ahmed Hamed, additional

Published
2023
Full Text
View/download PDF

73. Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma

Author

Hess, Georg, primary, Dreyling, Martin, additional, Oberic, Lucie, additional, Gine, Eva, additional, Zinzani, Pier Luigi, additional, Linton, Kim, additional, Vilmar, Adam, additional, Jerkeman, Mats, additional, Chen, Jenny M. H., additional, Ohler, Anke, additional, Stilgenbauer, Stephan, additional, Thieblemont, Catherine, additional, Lambert, Jonathan, additional, Zilioli, Vittorio Ruggero, additional, Sancho, Juan-Manuel, additional, Jimenez-Ubieto, Ana, additional, Fischer, Luca, additional, Eyre, Toby A., additional, Keeping, Sam, additional, Park, Julie E., additional, Wu, James J., additional, Nunes, Ana, additional, Reitan, John, additional, Wade, Sally W., additional, and Salles, Gilles, additional

Published
2023
Full Text
View/download PDF

74. Acquired BTK mutations associated with resistance to noncovalent BTK inhibitors

Author

Qi, Jialei, primary, Endres, Sascha, additional, Yosifov, Deyan Yordanov, additional, Tausch, Eugen, additional, Dheenadayalan, Rashmi Priyadharshini, additional, Gao, Xiang, additional, Müller, Annika, additional, Schneider, Christof, additional, Mertens, Daniel, additional, Gierschik, Peter, additional, Wist, Martin, additional, Jebaraj, Billy Michael Chelliah, additional, and Stilgenbauer, Stephan, additional

Published
2023
Full Text
View/download PDF

77. Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia

Author

Bloehdorn, Johannes, Braun, Andrejs, Taylor-Weiner, Amaro, Jebaraj, Billy Michael Chelliah, Robrecht, Sandra, Krzykalla, Julia, Pan, Heng, Giza, Adam, Akylzhanova, Gulnara, Holzmann, Karlheinz, Scheffold, Annika, Johnston, Harvey E., Yeh, Ru-Fang, Klymenko, Tetyana, Tausch, Eugen, Eichhorst, Barbara, Bullinger, Lars, Fischer, Kirsten, Weisser, Martin, Robak, Tadeusz, Schneider, Christof, Gribben, John, Dahal, Lekh N., Carter, Mathew J., Elemento, Olivier, Landau, Dan A., Neuberg, Donna S., Cragg, Mark S., Benner, Axel, Hallek, Michael, Wu, Catherine J., Döhner, Hartmut, Stilgenbauer, Stephan, and Mertens, Daniel

Published
2021
Full Text
View/download PDF

79. Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia

Author

Kipps, Thomas J., Fraser, Graeme, Coutre, Steven E., Brown, Jennifer R., Barrientos, Jacqueline C., Barr, Paul M., Byrd, John C., O’Brien, Susan M., Dilhuydy, Marie-Sarah, Hillmen, Peter, Jaeger, Ulrich, Moreno, Carol, Cramer, Paula, Stilgenbauer, Stephan, Chanan-Khan, Asher A., Mahler, Michelle, Salman, Mariya, Eckert, Karl, Solman, Isabelle G., Balasubramanian, Sriram, Cheng, Mei, Londhe, Anil, Ninomoto, Joi, Howes, Angela, James, Danelle F., and Hallek, Michael

Published
2019
Full Text
View/download PDF

80. Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study

Author

Herling, Carmen D, Coombes, Kevin R, Benner, Axel, Bloehdorn, Johannes, Barron, Lynn L, Abrams, Zachary B, Majewski, Tadeusz, Bondaruk, Jolanta E, Bahlo, Jasmin, Fischer, Kirsten, Hallek, Michael, Stilgenbauer, Stephan, Czerniak, Bogdan A, Oakes, Christopher C, Ferrajoli, Alessandra, Keating, Michael J, and Abruzzo, Lynne V

Published
2019
Full Text
View/download PDF

82. Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial

Author

Herling, Carmen D., Cymbalista, Florence, Groß-Ophoff-Müller, Carolin, Bahlo, Jasmin, Robrecht, Sandra, Langerbeins, Petra, Fink, Anna-Maria, Al-Sawaf, Othman, Busch, Raymonde, Porcher, Raphael, Cazin, Bruno, Dreyfus, Brigitte, Ibach, Stefan, Leprêtre, Stéphane, Fischer, Kirsten, Kaiser, Florian, Eichhorst, Barbara, Wentner, Clemens-Martin, Hoechstetter, Manuela A., Döhner, Hartmut, Leblond, Veronique, Kneba, Michael, Letestu, Remi, Böttcher, Sebastian, Stilgenbauer, Stephan, Hallek, Michael, and Levy, Vincent

Published
2020
Full Text
View/download PDF

83. COVID-19 among fit patients with CLL treated with venetoclax-based combinations

Author

Fürstenau, Moritz, Langerbeins, Petra, De Silva, Nisha, Fink, Anna Maria, Robrecht, Sandra, von Tresckow, Julia, Simon, Florian, Hohloch, Karin, Droogendijk, Jolanda, van der Klift, Marjolein, van der Spek, Ellen, Illmer, Thomas, Schöttker, Björn, Fischer, Kirsten, Wendtner, Clemens M., Tausch, Eugen, Stilgenbauer, Stephan, Niemann, Carsten U., Gregor, Michael, Kater, Arnon P., Hallek, Michael, and Eichhorst, Barbara

Published
2020
Full Text
View/download PDF

84. Prognostic model for newly diagnosed CLL patients in Binet stage A: results of the multicenter, prospective CLL1 trial of the German CLL study group

Author

Hoechstetter, Manuela A., Busch, Raymonde, Eichhorst, Barbara, Bühler, Andreas, Winkler, Dirk, Bahlo, Jasmin, Robrecht, Sandra, Eckart, Michael J., Vehling-Kaiser, Ursula, Jacobs, Georg, Jäger, Ulrich, Hurtz, Hans Jürgen, Hopfinger, Georg, Hartmann, Frank, Fuss, Harald, Abenhardt, Wolfgang, Blau, Ilona, Freier, Werner, Müller, Lothar, Goebeler, Maria, Wendtner, Clemens, Fischer, Kirsten, Herling, Carmen D., Starck, Michael, Bentz, Martin, Emmerich, Bertold, Döhner, Hartmut, Stilgenbauer, Stephan, and Hallek, Michael

Published
2020
Full Text
View/download PDF

85. Influence of obesity and gender on treatment outcomes in patients with chronic lymphocytic leukemia (CLL) undergoing rituximab-based chemoimmunotherapy

Author

Fürstenau, Moritz, Hopfinger, Georg, Robrecht, Sandra, Fink, Anna-Maria, Al-Sawaf, Othman, Langerbeins, Petra, Cramer, Paula, Tresckow, Julia Von, Maurer, Christian, Kutsch, Nadine, Hoechstetter, Manuela, Dreyling, Martin, Lange, Elisabeth, Kneba, Michael, Stilgenbauer, Stephan, Döhner, Hartmut, Hensel, Manfred, Kiehl, Michael G., Jaeger, Ulrich, Wendtner, Clemens-Martin, Goede, Valentin, Fischer, Kirsten, von Bergwelt-Baildon, Michael, Eichhorst, Barbara, Hallek, Michael, and Theurich, Sebastian

Published
2020
Full Text
View/download PDF

87. Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study

Author

Bosch, Francesc, Cantin, Guy, Cortelezzi, Agostino, Knauf, Wolfgang, Tiab, Mourad, Turgut, Mehmet, Zaritskey, Andrey, Merot, Jean-Louis, Tausch, Eugen, Trunzer, Kerstin, Robson, Susan, Gresko, Ekaterina, Böttcher, Sebastian, Foà, Robin, Stilgenbauer, Stephan, and Leblond, Véronique

Published
2020
Full Text
View/download PDF

88. Oxidative stress as candidate therapeutic target to overcome microenvironmental protection of CLL

Author

Yosifov, Deyan Yordanov, Idler, Irina, Bhattacharya, Nupur, Reichenzeller, Michaela, Close, Viola, Ezerina, Daria, Scheffold, Annika, Jebaraj, Billy Michael Chelliah, Kugler, Sabrina, Bloehdorn, Johannes, Bahlo, Jasmin, Robrecht, Sandra, Eichhorst, Barbara, Fischer, Kirsten, Weigel, Anja, Busch, Hauke, Lichter, Peter, Döhner, Hartmut, Dick, Tobias P., Stilgenbauer, Stephan, and Mertens, Daniel

Published
2020
Full Text
View/download PDF

89. Final results of EFC6663: A multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia

Author

Lanasa, Mark C, Andritsos, Leslie, Brown, Jennifer R, Gabrilove, Janice, Caligaris-Cappio, Federico, Ghia, Paolo, Larson, Richard A, Kipps, Thomas J, Leblond, Veronique, Milligan, Donald W, Janssens, Ann, Johnson, Amy J, Heerema, Nyla A, Bühler, Andreas, Stilgenbauer, Stephan, Devin, Jeanne, Hallek, Michael, Byrd, John C, and Grever, Michael R

Subjects
Rare Diseases, Cancer, Clinical Trials and Supportive Activities, Patient Safety, Lymphoma, Hematology, Clinical Research, Pediatric, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Female, Flavonoids, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Male, Middle Aged, Piperidines, Recurrence, Survival Analysis, Treatment Failure, Vidarabine, Chronic lymphocytic leukemia, Flavopiridol, Therapy, Tumor lysis syndrome, Cyclin dependent kinase inhibitor, Clinical Sciences, Immunology
Abstract

Early phase studies of alvocidib showed activity in relapsed CLL including patients with high risk genomic features and those refractory to fludarabine. A multi-center, international, phase II study of alvocidib in fludarabine refractory CLL was undertaken to validate these early results. Patients with fludarabine refractory CLL or prolymphocytic leukemia arising from CLL were treated with single agent alvocidib. The primary outcome measure was overall response rate, with secondary outcomes including survival, toxicity, and response duration. One hundred and sixty five patients were enrolled and 159 patients were treated. The median age was 61 years, the median number of prior therapies was 4, and 96% of patients were fludarabine refractory. The investigator-assessed overall response rate was 25%; the majority of responses were partial. Response rates were lower among patients with del(17p) (14%), but equivalent in patients with del(11q) or bulky lymphadenopathy. Median progression free and overall survival were 7.6 and 14.6 months, respectively. Tumor lysis occurred in 39 patients (25%), and 13 received hemodialysis. Diarrhea, fatigue, and hematologic toxicities were common. Alvocidib has clinical activity in patients with advanced, fludarabine refractory CLL. Future studies should focus on discovery of biomarkers of clinical response and tumor lysis, and enhanced supportive care measures.

Published
2015

92. IGF1R as druggable target mediating PI3K-δ inhibitor resistance in a murine model of chronic lymphocytic leukemia

Author

Scheffold, Annika, Jebaraj, Billy Michael Chelliah, Tausch, Eugen, Bloehdorn, Johannes, Ghia, Paolo, Yahiaoui, Anella, Dolnik, Anna, Blätte, Tamara Jacqueline, Bullinger, Lars, Dheenadayalan, Rashmi Priyadharshini, Li, Li, Schneider, Christof, Chen, Shih-Shih, Chiorazzi, Nicholas, Dietrich, Sascha, Seiffert, Martina, Tannheimer, Stacey, Döhner, Hartmut, Mertens, Daniel, and Stilgenbauer, Stephan

Published
2019
Full Text
View/download PDF

96. Hyper-N-glycosylated SAMD14 and neurabin-I as driver autoantigens of primary central nervous system lymphoma

Author

Thurner, Lorenz, Preuss, Klaus-Dieter, Bewarder, Moritz, Kemele, Maria, Fadle, Natalie, Regitz, Evi, Altmeyer, Sarah, Schormann, Claudia, Poeschel, Viola, Ziepert, Marita, Walter, Silke, Roth, Patrick, Weller, Michael, Szczepanowski, Monika, Klapper, Wolfram, Monoranu, Camelia, Rosenwald, Andreas, Möller, Peter, Hartmann, Sylvia, Hansmann, Martin-Leo, Mackensen, Andreas, Schäfer, Henning, Schorb, Elisabeth, Illerhaus, Gerald, Buslei, Rolf, Bohle, Rainer Maria, Stilgenbauer, Stephan, Kim, Yoo-Jin, and Pfreundschuh, Michael

Published
2018
Full Text
View/download PDF

97. The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL

Author

Flinn, Ian W., Hillmen, Peter, Montillo, Marco, Nagy, Zsolt, Illés, Árpád, Etienne, Gabriel, Delgado, Julio, Kuss, Bryone J., Tam, Constantine S., Gasztonyi, Zoltán, Offner, Fritz, Lunin, Scott, Bosch, Francesco, Davids, Matthew S., Lamanna, Nicole, Jaeger, Ulrich, Ghia, Paolo, Cymbalista, Florence, Portell, Craig A., Skarbnik, Alan P., Cashen, Amanda F., Weaver, David T., Kelly, Virginia M., Turnbull, Barry, and Stilgenbauer, Stephan

Published
2018
Full Text
View/download PDF

98. Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia

Author

Furman, Richard R, Sharman, Jeff P, Coutre, Steven E, Cheson, Bruce D, Pagel, John M, Hillmen, Peter, Barrientos, Jacqueline C, Zelenetz, Andrew D, Kipps, Thomas J, Flinn, Ian, Ghia, Paolo, Eradat, Herbert, Ervin, Thomas, Lamanna, Nicole, Coiffier, Bertrand, Pettitt, Andrew R, Ma, Shuo, Stilgenbauer, Stephan, Cramer, Paula, Aiello, Maria, Johnson, Dave M, Miller, Langdon L, Li, Daniel, Jahn, Thomas M, Dansey, Roger D, Hallek, Michael, and O'Brien, Susan M

Subjects
Cancer, Lymphoma, Clinical Research, Clinical Trials and Supportive Activities, Hematology, Patient Safety, Rare Diseases, Evaluation of treatments and therapeutic interventions, 6.2 Cellular and gene therapies, 6.1 Pharmaceuticals, Aged, Aged, 80 and over, Antibodies, Monoclonal, Murine-Derived, Antineoplastic Combined Chemotherapy Protocols, Disease-Free Survival, Double-Blind Method, Female, Humans, Kaplan-Meier Estimate, Kidney Diseases, Leukemia, Lymphocytic, Chronic, B-Cell, Lymph Nodes, Male, Middle Aged, Phosphoinositide-3 Kinase Inhibitors, Purines, Quinazolinones, Recurrence, Rituximab, Medical and Health Sciences, General & Internal Medicine
Abstract

BackgroundPatients with relapsed chronic lymphocytic leukemia (CLL) who have clinically significant coexisting medical conditions are less able to undergo standard chemotherapy. Effective therapies with acceptable side-effect profiles are needed for this patient population.MethodsIn this multicenter, randomized, double-blind, placebo-controlled, phase 3 study, we assessed the efficacy and safety of idelalisib, an oral inhibitor of the delta isoform of phosphatidylinositol 3-kinase, in combination with rituximab versus rituximab plus placebo. We randomly assigned 220 patients with decreased renal function, previous therapy-induced myelosuppression, or major coexisting illnesses to receive rituximab and either idelalisib (at a dose of 150 mg) or placebo twice daily. The primary end point was progression-free survival. At the first prespecified interim analysis, the study was stopped early on the recommendation of the data and safety monitoring board owing to overwhelming efficacy.ResultsThe median progression-free survival was 5.5 months in the placebo group and was not reached in the idelalisib group (hazard ratio for progression or death in the idelalisib group, 0.15; P

Published
2014

99. Evolution of DNA Methylation Is Linked to Genetic Aberrations in Chronic Lymphocytic Leukemia

Author

Oakes, Christopher C, Claus, Rainer, Gu, Lei, Assenov, Yassen, Hüllein, Jennifer, Zucknick, Manuela, Bieg, Matthias, Brocks, David, Bogatyrova, Olga, Schmidt, Christopher R, Rassenti, Laura, Kipps, Thomas J, Mertens, Daniel, Lichter, Peter, Döhner, Hartmut, Stilgenbauer, Stephan, Byrd, John C, Zenz, Thorsten, and Plass, Christoph

Subjects
Rare Diseases, Genetic Testing, Genetics, Cancer, Lymphoma, Human Genome, Hematology, Good Health and Well Being, Aged, Chromosomes, Human, CpG Islands, DNA Methylation, Disease Progression, Epigenesis, Genetic, Female, Gene Expression Regulation, Leukemic, Genetic Heterogeneity, Genome, Human, Genomic Instability, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Male, Middle Aged, Oncology and Carcinogenesis
Abstract

Although clonal selection by genetic driver aberrations in cancer is well documented, the ability of epigenetic alterations to promote tumor evolution is undefined. We used 450k arrays and next-generation sequencing to evaluate intratumor heterogeneity and evolution of DNA methylation and genetic aberrations in chronic lymphocytic leukemia (CLL). CLL cases exhibit vast interpatient differences in intratumor methylation heterogeneity, with genetically clonal cases maintaining low methylation heterogeneity and up to 10% of total CpGs in a monoallelically methylated state. Increasing methylation heterogeneity correlates with advanced genetic subclonal complexity. Selection of novel DNA methylation patterns is observed only in cases that undergo genetic evolution, and independent genetic evolution is uncommon and is restricted to low-risk alterations. These results reveal that although evolution of DNA methylation occurs in high-risk, clinically progressive cases, positive selection of novel methylation patterns entails coevolution of genetic alteration(s) in CLL.

Published
2014

100. Predictive Value of Minimal Residual Disease for Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results From the European Mantle Cell Lymphoma Elderly Trial.

Author

Hoster, Eva, Delfau-Larue, Marie-Hélène, Macintyre, Elizabeth, Jiang, Linmiao, Stilgenbauer, Stephan, Vehling-Kaiser, Ursula, Salles, Gilles, Thieblemont, Catherine, Tilly, Hervé, Wirths, Stefan, Feugier, Pierre, Hübel, Kai, Schmidt, Christian, Ribrag, Vincent, Kluin-Nelemans, Johanna C., Dreyling, Martin, and Pott, Christiane

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results